Compass Therapeutics (CMPX) EBIT Margin (2024)
Compass Therapeutics' EBIT Margin history spans 1 years, with the latest figure at 1769.88% for Q2 2024.
- For Q2 2024, EBIT Margin changed N/A year-over-year to 1769.88%; the TTM value through Mar 2025 reached 7273.06%, changed N/A, while the annual FY2024 figure was 6661.76%, N/A changed from the prior year.
- EBIT Margin for Q2 2024 was 1769.88% at Compass Therapeutics.
- Across five years, EBIT Margin topped out at 1769.88% in Q2 2024 and bottomed at 1769.88% in Q2 2024.